Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company`s onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Website: cardiffoncology.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. Gross margin is high, +100.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 4.5% (LTM)

Entry Point: Share price is 324.0% higher than minimum and 59.5% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: CRDF
Share price, USD:  (+2.0%)4.07
year average price 2.07  


year start price 1.86 2023-05-01

min close price 0.96 2023-10-24

max close price 5.91 2024-03-25

current price 4.07 2024-04-29
Common stocks: 43 306 101

Dividend Yield:  0.0%
Last revenue growth (y/y):  0.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 176
Net Debt ($m): -18
EV (Enterprise Value): 158
Price to Book: 2.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-25GlobeNewsWire

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

2024-04-01Zacks Investment Research

Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why

2024-03-21Zacks Investment Research

Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why

2024-03-14Zacks Investment Research

Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going

2024-03-14Zacks Investment Research

Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last?

2024-03-08Seeking Alpha

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

2024-03-06Zacks Investment Research

What Makes Cardiff Oncology (CRDF) a Strong Momentum Stock: Buy Now?

2024-02-29Zacks Investment Research

Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates

2023-11-02Seeking Alpha

Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call Transcript

2023-10-11Zacks Investment Research

Cardiff Oncology (CRDF) Loses -29.75% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CRDF CRDF CRDF CRDF CRDF CRDF
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-29 2023-11-02 2023-08-09 2023-05-04 2023-03-02 2022-11-03
acceptedDate 2024-02-29 16:00:21 2023-11-02 16:02:08 2023-08-09 16:01:02 2023-05-04 16:00:51 2023-03-02 16:01:11 2022-11-03 16:00:17
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 156 000 141 000 108 000 83 000 128 000 93 000
costOfRevenue 103 000 107 000 98 000 0 0 0
grossProfit 53 000 34 000 10000.000 83 000 128 000 93 000
grossProfitRatio 0.340 0.241 0.093 1.000 1.000 1.000
researchAndDevelopmentExpenses 8M 8M 8M 9M 6M 6M
generalAndAdministrativeExpenses 3M 3M 4M 3M 3M 3M
sellingAndMarketingExpenses -8M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 3M 3M 4M 3M 3M 3M
otherExpenses -13 000 21 000 5000.000 -111 000 -45 000 0
operatingExpenses 10M 11M 12M 12M 10M 9M
costAndExpenses 10M 11M 12M 12M 10M 9M
interestIncome 1M 1M 1M 940 000 740 000 458 000
interestExpense 829 000 0 0 -829 000 740 000 458 000
depreciationAndAmortization 103 000 107 000 98 000 90 000 86 000 81 000
ebitda -10M -11M -12M -12M -9M -9M
ebitdaratio -65.571 -75.979 -112.130 -144.120 -72.703 -95.828
operatingIncome -10M -11M -12M -12M -9M -9M
operatingIncomeRatio -66.231 -76.738 -113.037 -145.205 -73.375 -96.699
totalOtherIncomeExpensesNet 995 000 21 000 5000.000 829 000 695 000 422 000
incomeBeforeTax -9M -10M -11M -11M -9M -9M
incomeBeforeTaxRatio -59.853 -69.014 -103.241 -135.217 -67.945 -92.161
incomeTaxExpense 3M -1M -1M -829 000 -695 000 -422 000
netIncome -9M -10M -11M -10M -8M -8M
netIncomeRatio -59.853 -69.014 -103.241 -125.229 -62.516 -87.624
eps -0.210 -0.220 -0.250 -0.230 -0.180 -0.190
epsdiluted -0.210 -0.220 -0.250 -0.230 -0.180 -0.190
weightedAverageShsOut 45M 45M 45M 45M 44M 43M
weightedAverageShsOutDil 45M 45M 45M 45M 44M 43M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CRDF CRDF CRDF CRDF CRDF CRDF
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-29 2023-11-02 2023-08-09 2023-05-04 2023-03-02 2022-11-03
acceptedDate 2024-02-29 16:00:21 2023-11-02 16:02:08 2023-08-09 16:01:02 2023-05-04 16:00:51 2023-03-02 16:01:11 2022-11-03 16:00:17
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 22M 15M 19M 15M 16M 19M
shortTermInvestments 53M 66M 70M 82M 89M 96M
cashAndShortTermInvestments 75M 81M 89M 97M 105M 114M
netReceivables 288 000 198 000 161 000 676 000 771 000 650 000
inventory 0 0 1.000 0 0 0
otherCurrentAssets 2M 2M 3M 4M 5M 5M
totalCurrentAssets 77M 84M 93M 102M 111M 120M
propertyPlantEquipmentNet 3M 3M 3M 3M 4M 4M
goodwill 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 1M 1M 1M 1M 1M 184 000
totalNonCurrentAssets 4M 5M 5M 5M 5M 4M
otherAssets 1.000 0 0 0 0 0
totalAssets 82M 88M 97M 107M 116M 124M
accountPayables 2M 2M 3M 3M 2M 1M
shortTermDebt 691 000 688 000 683 000 679 000 675 000 674 000
taxPayables 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0
otherCurrentLiabilities 8M 6M 6M 5M 5M 6M
totalCurrentLiabilities 10M 9M 9M 8M 8M 8M
longTermDebt 1M 2M 2M 2M 2M 2M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 75 000
totalNonCurrentLiabilities 1M 2M 2M 2M 2M 2M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 1M 2M 2M 3M 3M 3M
totalLiabilities 12M 11M 11M 10M 10M 10M
preferredStock 0 0 0 0 0 0
commonStock 4000.000 4000.000 4000.000 4000.000 4000.000 4000.000
retainedEarnings -340M -330M -320M -309M -298M -290M
accumulatedOtherComprehensiveIncomeLoss -67 000 -407 000 -431 000 -76 000 -395 000 -779 000
othertotalStockholdersEquity 409M 408M 407M 406M 405M 404M
totalStockholdersEquity 70M 78M 87M 97M 106M 113M
totalEquity 70M 78M 87M 97M 106M 113M
totalLiabilitiesAndStockholdersEquity 82M 88M 97M 107M 116M 124M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 82M 88M 97M 107M 116M 124M
totalInvestments 53M 66M 70M 82M 89M 96M
totalDebt 2M 2M 2M 3M 3M 3M
netDebt -20M -13M -17M -12M -14M -16M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CRDF CRDF CRDF CRDF CRDF CRDF
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-29 2023-11-02 2023-08-09 2023-05-04 2023-03-02 2022-11-03
acceptedDate 2024-02-29 16:00:21 2023-11-02 16:02:08 2023-08-09 16:01:02 2023-05-04 16:00:51 2023-03-02 16:01:11 2022-11-03 16:00:17
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -9M -10M -11M -11M -9M -9M
depreciationAndAmortization 103 000 107 000 98 000 90 000 86 000 81 000
deferredIncomeTax 21M -10M -11M 0 0 0
stockBasedCompensation 909 000 955 000 2M 1M 1M 1M
changeInWorkingCapital 1M 1M 3M 2M -2M -148 000
accountsReceivables -90 000 -37 000 515 000 95 000 -236 000 0
inventory -3M 0 0 0 0 0
accountsPayables 1M 135 000 1M 203 000 1M 0
otherWorkingCapital 3M 925 000 976 000 1M -3M 0
otherNonCashItems -22M 10M 11M -163 000 -39 000 115 000
netCashProvidedByOperatingActivities -7M -8M -7M -9M -9M -7M
investmentsInPropertyPlantAndEquipment -8000.000 -315 000 -251 000 -8000.000 -75 000 -448 000
acquisitionsNet 7M 315 000 251 000 0 0 0
purchasesOfInvestments -3M -17M -14M -37M -11M -23M
salesMaturitiesOfInvestments 16M 21M 25M 45M 18M 29M
otherInvestingActivites -7M -315 000 -251 000 0 0 43 000
netCashUsedForInvestingActivites 14M 4M 11M 7M 7M 5M
debtRepayment 0 0 0 0 0 0
commonStockIssued 0 0 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 -6000.000 0 -414 000 0
otherFinancingActivites 24 000 6000.000 6000.000 0 414 000 75 000
netCashUsedProvidedByFinancingActivities 12 000 -6000.000 -6000.000 0 0 75 000
effectOfForexChangesOnCash 21M -6M -16M 0 0 0
netChangeInCash 6M -4M 4M -1M -2M -2M
cashAtEndOfPeriod 22M 15M 19M 15M 16M 19M
cashAtBeginningOfPeriod 15M 19M 15M 16M 19M 21M
operatingCashFlow -7M -8M -7M -9M -9M -7M
capitalExpenditure -8000.000 -315 000 -251 000 -8000.000 -75 000 -448 000
freeCashFlow -7M -8M -7M -9M -9M -8M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-29 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)

Press-releases

Show financial reports only

2024-02-29 21:07 ET
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
2024-02-29 21:06 ET
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
2024-02-29 21:05 ET
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
2024-02-26 13:00 ET
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
2024-02-22 13:00 ET
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
2024-01-17 15:30 ET
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
2023-11-20 21:05 ET
Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference
2023-11-02 20:05 ET
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
2023-10-26 20:05 ET
Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update
2023-09-26 20:05 ET
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy
2023-09-05 12:00 ET
Cardiff Oncology to Present at Upcoming Investor Conferences in September
2023-08-09 20:05 ET
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update
2023-08-07 20:05 ET
Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship
2023-07-24 21:09 ET
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-06-20 21:22 ET
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-06-05 12:00 ET
Cardiff Oncology to Present at the Jefferies Healthcare Conference
2023-05-04 20:10 ET
Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update
2023-03-28 12:00 ET
Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer
2023-03-06 13:15 ET
Cardiff Oncology Formally Introduces Scientific Advisory Board
2023-03-02 21:10 ET
Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
2023-02-27 13:15 ET
Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference
2023-02-02 13:00 ET
Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer
2023-01-10 13:00 ET
Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference
2022-11-21 15:52 ET
Cardiff Oncology to Present at Upcoming Investor Conferences
2022-11-08 13:15 ET
Cardiff Oncology to Present at the Jefferies London Healthcare Conference
2022-11-03 20:10 ET
Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates
2022-09-12 20:05 ET
Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates
2022-09-10 11:30 ET
Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022
2022-09-08 12:15 ET
Cardiff Oncology to Present at Upcoming Investor Conferences in September
2022-09-06 12:00 ET
Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022
2022-08-29 12:00 ET
Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022
2022-08-04 20:10 ET
Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates
2022-07-05 12:30 ET
Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022
2022-05-17 12:30 ET
Cardiff Oncology to Present at the H.C. Wainwright Global Investment Conference
2022-05-05 20:10 ET
Cardiff Oncology Reports First Quarter 2022 Results and Provides Business Updates
2022-04-12 20:00 ET
Cardiff Oncology Announces Departure of Chief Medical Officer
2022-04-08 17:05 ET
Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Models
2022-04-08 17:05 ET
Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting
2022-03-22 13:05 ET
Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC
2022-03-08 21:45 ET
Cardiff Oncology Announces Upcoming Poster Presentations at the AACR Annual Meeting
2022-03-01 13:30 ET
Cardiff Oncology to Participate in Cowen's 42nd Annual Healthcare Conference
2022-02-24 21:10 ET
Cardiff Oncology Reports Fourth Quarter and Full Year 2021 Results and Recent Highlights
2022-01-31 23:22 ET
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-01-20 18:46 ET
Cardiff Oncology to Present at the B. Riley Securities 2022 Oncology Conference
2022-01-18 22:00 ET
Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival
2022-01-11 13:00 ET
Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs
2022-01-10 13:00 ET
Cardiff Oncology to Host Conference Call and Webcast to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Being Presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
2022-01-04 13:00 ET
Cardiff Oncology to Present at the H.C. Wainwright BioConnect Virtual Conference
2021-12-10 13:30 ET
Cardiff Oncology Announces Upcoming Presentation on Lead KRAS-mutated Metastatic Colorectal Cancer Program at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
2021-12-03 13:30 ET
Cardiff Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-11-18 12:00 ET
Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative
2021-11-09 13:30 ET
Cardiff Oncology to Present at Upcoming Jefferies London Healthcare and Piper Sandler 33rd Annual Investor Conferences
2021-11-04 20:15 ET
Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business Updates
2021-09-08 20:00 ET
Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival
2021-09-07 12:30 ET
Cardiff Oncology to Present at Upcoming Investor Conferences in September
2021-08-25 12:15 ET
Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer on September 8, 2021
2021-08-05 20:15 ET
Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates
2021-07-12 12:00 ET
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
2021-07-06 12:30 ET
Cardiff Oncology to Participate in a Fireside Chat at the William Blair Biotech Focus Conference 2021
2021-06-28 12:30 ET
Cardiff Oncology Added to the Russell 2000® and other FTSE Russell Indexes
2021-06-10 16:30 ET
Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors
2021-06-08 12:30 ET
Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer
2021-05-20 12:30 ET
Cardiff Oncology to Present at the Jefferies Virtual Healthcare Conference
2021-05-06 20:10 ET
Cardiff Oncology Announces First Quarter 2021 Results and Recent Highlights
2021-04-12 10:00 ET
Cardiff Oncology Announces Onvansertib Phase 1b/2 Data that Continues to Demonstrate Robust Response to Treatment and Progression-Free Survival in KRAS-Mutated mCRC
2021-04-10 12:30 ET
Cardiff Oncology in Collaboration with MIT Presents Gene Signature Analyses Data Identifying Androgen-Independent Mechanism for Onvansertib-Abiraterone Synergy in mCRPC
2021-04-10 12:30 ET
Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRC
2021-04-08 12:30 ET
Cardiff Oncology to Host Key Opinion Leader Webinar on Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer
2021-03-11 13:30 ET
Cardiff Oncology to Present at the Oppenheimer 31st Annual Healthcare Conference
2021-03-10 21:30 ET
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2021
2021-03-03 13:30 ET
Cardiff Oncology to Present at H.C. Wainwright Global Life Sciences Conference
2021-02-25 21:10 ET
Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights
2021-02-24 13:30 ET
Cardiff Oncology to Participate in Gastrointestinal (GI) Oncology and Pancreatic Cancer Panel Discussion at the Cowen 41st Annual Health Care Conference
2021-02-16 16:54 ET
Cardiff Oncology to Present at the LifeSci Partners Precision Oncology Day
2021-02-11 13:00 ET
Cardiff Oncology Presents Phase 2 mCRPC Trial Data Showing a Two-Fold Increase in Efficacy with an Optimized Onvansertib Dosing Schedule
2021-01-26 13:00 ET
Cardiff Oncology Receives "Study May Proceed" from FDA to Initiate Phase 2 Trial of Onvansertib in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
2021-01-15 13:00 ET
Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program
2020-12-21 21:15 ET
Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board
2020-12-06 13:30 ET
Cardiff Oncology Presents Data at ASH Demonstrating the Safety and Anti-Leukemic Activity of Onvansertib in Patients with Relapsed/Refractory AML
2020-11-23 13:30 ET
Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference
2020-11-05 21:05 ET
Cardiff Oncology Announces Third Quarter 2020 Results and Highlights
2020-10-20 12:30 ET
Cardiff Oncology Presents Positive Efficacy and Biomarker Data from mCRPC Trial Demonstrating Ability of Onvansertib to Overcome Zytiga® Resistance
2020-09-30 04:14 ET
Cardiff Oncology Prices Public Offering
2020-09-29 20:02 ET
Cardiff Oncology Announces Proposed Public Offering
2020-09-17 12:00 ET
Cardiff Oncology Presents Data at ESMO Confirming Efficacy of Onvansertib and Durability of Response in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
2020-09-15 12:30 ET
Cardiff Oncology to Host Key Opinion Leader Call Discussing KRAS-Mutated Colorectal Cancer and Highlighting Data from Onvansertib Phase 1b/2 Trial
2020-09-14 12:30 ET
Cardiff Oncology to Present Data Further Demonstrating the Safety and Efficacy of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer Patients
2020-08-11 20:15 ET
Cardiff Oncology Announces Second Quarter 2020 Results and Highlights
2020-08-04 12:30 ET
Cardiff Oncology to Participate in Fireside Chat at the Virtual BTIG Biotechnology Conference
2020-07-30 12:30 ET
Cardiff Oncology to Participate in the William Blair Biotech Focus Conference
2020-06-16 12:30 ET
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital
2020-06-15 12:30 ET
Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML
2020-06-09 12:15 ET
Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation
2020-05-29 12:30 ET
Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO
2020-05-28 12:15 ET
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
2020-05-27 12:15 ET
Cardiff Oncology Announces $2.5 Million Equity Investment by Biotech-Focused Fundamental Investor Acorn Bioventures
2020-05-19 12:15 ET
Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer
2020-05-13 12:15 ET
Cardiff Oncology Enters Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
2020-05-07 20:15 ET
Trovagene Announces First Quarter 2020 Results and Highlights
2020-05-06 12:15 ET
Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer
2020-04-28 12:15 ET
Onvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable Response
2020-04-22 12:30 ET
Trovagene Expands Board with Addition of Three Industry Leaders - James Armitage, MD, Lâle White, and Gary Pace, PhD
2020-04-08 12:30 ET
Trovagene to Present at the 19th Annual Needham Healthcare Conference
2020-04-01 12:15 ET
Trovagene Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer (mCRC) Trial Abstract for Presentation at the 2020 ASCO Annual Meeting
2020-03-05 13:15 ET
Trovagene Announces Three New Nominees for Election to Board of Directors
2020-02-27 21:15 ET
Trovagene Announces Fourth Quarter and Full-Year 2019 Results
2020-02-13 13:00 ET
Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients
2020-02-05 13:00 ET
Trovagene to Present New Clinical Data for Onvansertib in Metastatic Castration-Resistant Prostate Cancer at ASCO Genitourinary Cancers Symposium
2020-01-29 13:00 ET
Trovagene Receives Approximately $1.45 Million From Exercise of Warrants
2020-01-27 13:00 ET
Onvasertib Demonstrates Effectiveness as Pan-KRAS Inhibitor with Confirmed Tumor Regression and Clinical Benefit Achieved in KRAS-Mutated mCRC Patients
2020-01-21 13:00 ET
Trovagene to Present New Clinical Data for Onvansertib in Metastatic KRAS-Mutated Colorectal Cancer at ASCO 2020 Gastrointestinal Cancers Symposium
2019-12-09 13:00 ET
Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASH
2019-12-04 13:00 ET
Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in Acute Myeloid Leukemia (AML)
2019-11-14 13:00 ET
Trovagene Presents Positive Data in Metastatic Prostate Cancer Phase 2 Trial Showing Clinical Response in Patients Resistant to Zytiga®
2019-11-07 21:20 ET
Trovagene Announces Third Quarter 2019 Results and Highlights
2019-11-06 14:00 ET
Trovagene Announces Data from Acute Myeloid Leukemia (AML) Phase 1b/2 Trial of Onvansertib Chosen for Oral Presentation at ASH 2019 Annual Meeting
2019-10-25 17:37 ET
Trovagene Announces $5.0 Million Private Placement Priced At-the-Market
2019-10-22 12:15 ET
Trovagene Announces Positive Response to Treatment in Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer
2019-10-02 12:15 ET
Data Presented at ESMO Provides Rationale for Clinical Trial of Onvansertib in Subset of Patients with Highly-Aggressive Triple Negative Breast Cancer (TNBC)
2019-10-01 12:15 ET
Trovagene Presents Overview of Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC) at ESMO
2019-09-30 12:15 ET
Positive Data from Trovagene Phase 1b/2 Study of Onvansertib Featured in Oral Presentation at European Society for Medical Oncology (ESMO) Conference
2019-09-19 12:15 ET
Trovagene Announces Successful Completion of Phase 1b Trial of Onvansertib in Acute Myeloid Leukemia (AML) and Initiation of Patient Enrollment in Phase 2
2019-09-03 12:15 ET
Trovagene to Present at the H.C. Wainwright 21st Annual Global Investment Conference
2019-08-26 12:00 ET
Trovagene Presents Positive Clinical Data from Ongoing Phase 2 Study of Onvansertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2019-08-15 12:15 ET
Trovagene to Present New Data from Onvansertib Phase 2 Study in Metastatic Castration-Resistant Prostate Cancer at Asia-Pacific Prostate Cancer Conference
2019-08-08 20:15 ET
Trovagene Announces Second Quarter 2019 Results and Highlights
2019-07-22 12:30 ET
ESMO Accepts Trovagene AML Clinical Trial Abstract for Oral Presentation
2019-07-15 12:30 ET
Trovagene Commences Non-Deal Investor Roadshow
2019-07-09 12:00 ET
Trovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer Centers
2019-05-30 21:50 ET
Trovagene to Host Business Update Conference Call on June 7, 2019
2019-05-23 12:00 ET
Trovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD(TM) in Models of Colorectal Cancer
2019-04-05 12:15 ET
Trovagene Announces Update to Phase 1b/2 AML Trial Data Presented at AACR - Additional Patients Achieve Complete Response at Two Highest Dose Levels of Onvansertib
2019-04-05 12:00 ET
Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital
2019-04-02 12:00 ET
Early Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy
2019-04-01 17:00 ET
Phase 1b/2 Dose Escalation Trial of Onvansertib in Relapsed/Refractory AML Demonstrates Safety, Tolerability and Relative Durability with Complete Responses at Highest Dose Levels

SEC forms

Show financial reports only

SEC form 8
2024-02-29 16:08 ET
Cardiff Oncology published news for 2023 q4
SEC form 8
2024-02-29 16:08 ET
Cardiff Oncology published news for 2023 q4
SEC form 8
2024-02-29 16:08 ET
Cardiff Oncology published news for 2023 q4
SEC form 8
2024-02-29 16:08 ET
Cardiff Oncology published news for 2023 q4
SEC form 8
2024-02-29 16:08 ET
Cardiff Oncology reported for 2023 q4
SEC form 10
2024-02-29 16:00 ET
Cardiff Oncology reported for 2023 q4
SEC form 10
2024-02-29 00:00 ET
Cardiff Oncology reported for 2023 q4
SEC form 8
2023-11-02 16:06 ET
Cardiff Oncology reported for 2023 q3
SEC form 10
2023-11-02 16:02 ET
Cardiff Oncology reported for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Cardiff Oncology reported for 2023 q3
SEC form 6
2023-08-09 16:06 ET
Cardiff Oncology reported for 2023 q2
SEC form 10
2023-08-09 16:01 ET
Cardiff Oncology reported for 2023 q2
SEC form 8
2023-08-09 00:00 ET
Cardiff Oncology reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Cardiff Oncology reported for 2023 q2
SEC form 6
2023-08-07 16:42 ET
Cardiff Oncology published news for 2023 q2
SEC form 6
2023-07-24 17:13 ET
Cardiff Oncology published news for 2023 q2
SEC form 6
2023-06-20 17:24 ET
Cardiff Oncology published news for 2023 q1
SEC form 6
2023-06-15 16:45 ET
Cardiff Oncology published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Cardiff Oncology reported for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Cardiff Oncology reported for 2023 q1
SEC form 6
2023-03-10 16:51 ET
Cardiff Oncology published news for 2022 q4
SEC form 6
2023-03-02 16:14 ET
Cardiff Oncology reported for 2022 q4
SEC form 10
2023-03-02 16:01 ET
Cardiff Oncology reported for 2022 q4
SEC form 10
2023-03-02 00:00 ET
Cardiff Oncology reported for 2022 q4
SEC form 8
2023-03-02 00:00 ET
Cardiff Oncology reported for 2022 q4
SEC form 6
2023-02-02 16:02 ET
Cardiff Oncology published news for 2022 q4
SEC form 6
2022-11-03 16:14 ET
Cardiff Oncology reported for 2022 q3
SEC form 10
2022-11-03 16:00 ET
Cardiff Oncology reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Cardiff Oncology reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Cardiff Oncology reported for 2022 q3
SEC form 6
2022-10-03 16:12 ET
Cardiff Oncology published news for 2022 q3
SEC form 6
2022-09-12 16:09 ET
Cardiff Oncology published news for 2022 q2
SEC form 6
2022-09-06 16:07 ET
Cardiff Oncology published news for 2022 q2
SEC form 6
2022-08-04 16:08 ET
Cardiff Oncology published news for 2022 q2
SEC form 10
2022-08-04 16:02 ET
Cardiff Oncology published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Cardiff Oncology reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Cardiff Oncology reported for 2022 q2
SEC form 6
2022-06-14 16:08 ET
Cardiff Oncology published news for 2022 q1
SEC form 6
2022-06-09 17:02 ET
Cardiff Oncology published news for 2022 q1
SEC form 6
2022-05-05 16:03 ET
Cardiff Oncology published news for 2022 q1
SEC form 10
2022-05-05 16:00 ET
Cardiff Oncology published news for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Cardiff Oncology reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Cardiff Oncology reported for 2022 q1
SEC form 6
2022-04-14 16:02 ET
Cardiff Oncology published news for 2022 q1
SEC form 6
2022-04-12 16:11 ET
Cardiff Oncology published news for 2022 q1
SEC form 6
2022-04-08 15:34 ET
Cardiff Oncology published news for 2022 q1
SEC form 6
2022-02-24 16:09 ET
Cardiff Oncology published news for 2021 q4
SEC form 10
2022-02-24 16:00 ET
Cardiff Oncology published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Cardiff Oncology published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Cardiff Oncology published news for 2021 q4
SEC form 6
2022-01-31 17:29 ET
Cardiff Oncology published news for 2021 q4
SEC form 6
2022-01-18 17:00 ET
Cardiff Oncology published news for 2021 q4
SEC form 6
2022-01-11 10:09 ET
Cardiff Oncology published news for 2021 q4
SEC form 6
2021-12-10 11:14 ET
Cardiff Oncology published news for 2021 q3
SEC form 6
2021-12-03 11:05 ET
Cardiff Oncology published news for 2021 q3
SEC form 6
2021-11-18 08:56 ET
Cardiff Oncology published news for 2021 q3
SEC form 6
2021-11-10 12:54 ET
Cardiff Oncology published news for 2021 q3
SEC form 6
2021-11-04 16:01 ET
Cardiff Oncology published news for 2021 q3
SEC form 10
2021-11-04 16:00 ET
Cardiff Oncology published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Cardiff Oncology published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Cardiff Oncology published news for 2021 q3
SEC form 6
2021-09-08 16:00 ET
Cardiff Oncology published news for 2021 q2
SEC form 6
2021-09-07 11:15 ET
Cardiff Oncology published news for 2021 q2
SEC form 6
2021-08-25 13:23 ET
Cardiff Oncology published news for 2021 q2
SEC form 10
2021-08-05 16:03 ET
Cardiff Oncology published news for 2021 q2
SEC form 6
2021-08-05 16:01 ET
Cardiff Oncology published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Cardiff Oncology published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Cardiff Oncology published news for 2021 q2
SEC form 6
2021-07-12 11:13 ET
Cardiff Oncology published news for 2021 q2
SEC form 6
2021-07-06 12:35 ET
Cardiff Oncology published news for 2021 q2
SEC form 6
2021-06-28 13:33 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-06-10 16:07 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-06-08 08:41 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-06-01 10:52 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-05-20 10:36 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-05-06 16:01 ET
Cardiff Oncology published news for 2021 q1
SEC form 10
2021-05-06 15:59 ET
Cardiff Oncology published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-04-28 16:01 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-04-12 08:33 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-04-08 15:03 ET
Cardiff Oncology published news for 2021 q1
SEC form 6
2021-03-11 13:43 ET
Cardiff Oncology published news for 2020 q4
SEC form 6
2021-03-03 12:57 ET
Cardiff Oncology published news for 2020 q4
SEC form 6
2021-02-25 16:02 ET
Cardiff Oncology published news for 2020 q4
SEC form 10
2021-02-25 16:01 ET
Cardiff Oncology published news for 2020 q4
SEC form 6
2021-02-24 11:21 ET
Cardiff Oncology published news for 2020 q4
SEC form 6
2021-02-16 13:43 ET
Cardiff Oncology published news for 2020 q4
SEC form 6
2021-02-11 10:39 ET
Cardiff Oncology published news for 2020 q4
SEC form 6
2021-01-26 11:19 ET
Cardiff Oncology published news for 2020 q4
SEC form 6
2021-01-15 11:34 ET
Cardiff Oncology published news for 2020 q4
SEC form 6
2020-12-21 16:18 ET
Cardiff Oncology published news for 2020 q3
SEC form 6
2020-12-07 13:22 ET
Cardiff Oncology published news for 2020 q3
SEC form 6
2020-11-23 11:54 ET
Cardiff Oncology published news for 2020 q3
SEC form 6
2020-11-05 16:09 ET
Cardiff Oncology published news for 2020 q3
SEC form 10
2020-11-05 16:00 ET
Cardiff Oncology published news for 2020 q3
SEC form 6
2020-10-20 11:59 ET
Cardiff Oncology published news for 2020 q3
SEC form 6
2020-09-30 16:09 ET
Cardiff Oncology published news for 2020 q2